uPAR

uPAR 분자 정보

영어 이름Urokinase plasminogen activator surface receptor시판 약물 수0
임상 약물 수7표적 별명Monocyte activation antigen Mo3,U-PAR,uPAR,CD87,Urokinase-Type Plasminogen Activator (UPA) Receptor,URKR,U-Plasminogen Activator Receptor Form 2,CD87 Antigen,Plasminogen Activator, Urokinase Receptor,MO3
최고 연구 개발 단계Phase 3 Clinical
영어 이름Urokinase plasminogen activator surface receptor
표적 별명Monocyte activation antigen Mo3,U-PAR,uPAR,CD87,Urokinase-Type Plasminogen Activator (UPA) Receptor,URKR,U-Plasminogen Activator Receptor Form 2,CD87 Antigen,Plasminogen Activator, Urokinase Receptor,MO3
시판 약물 수0
임상 약물 수7
최고 연구 개발 단계Phase 3 Clinical

uPAR 제품 목록

  • 속성

    Protein (17)Cell (2)Beads (1)

  • 제품 라이브러리

    온라인 (20)

  • Human (12)Mouse (5)Cynomolgus (1)Rat (2)

  • 태그

    His Tag (9)His Tag & Avi Tag (5)Fc Tag (3)- (3)

  • 마커

    Unconjugated (9)Biotin-labeled (5)FITC Labeled (1)PE Labeled (1)APC Labeled (1)- (3)

uPAR분자 배경

Urokinase plasminogen activator surface receptor (U-PAR) is also known as PLAUR, Monocyte activation antigen Mo3, CD antigen CD87. PLAUR contains three UPAR/Ly6 domains. U-PAR is expressed in neurons of the rolandic area of the brain (at protein level) and is also expressed in the brain. PLAUR / CD87 interacts with MRC2, SRPX2 and SORL1. PLAUR / UPAR acts as a receptor for urokinase plasminogen activator and plays a role in localizing and promoting plasmin formation. U-PAR mediates the proteolysis-independent signal transduction activation effects of U-PA.

uPAR분자 별명

uPAR,PLAUR,CD87,MO3

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
Gallium-68 NOTA AE105CS-001; 68Ga-NOTA-AE105Phase 3 ClinicalCurasight Aps, RigshospitaletBone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Genital Neoplasms, Female; Glioblastoma; Hair Diseases; Head and Neck Neoplasms; Mesothelioma; Mouth Neoplasms; Neoplasms; Neuroendocrine Tumors; Oropharyngeal Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms
상세
WAL0921WAL0921; WAL-0921; WAL 0921Phase 2 ClinicalWalden Biosciences IncDiabetic Nephropathies; Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Glomerulosclerosis, Focal Segmental; Kidney Diseases; Nephrosis, Lipoid; Renal Insufficiency, Chronic
상세
64Cu-DOTA-AE10564Cu-DOTA-AE105Phase 2 ClinicalRigshospitaletBreast Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms
상세
FG-001FG001; FG-001Phase 2 ClinicalFluoGuide ASBrain Neoplasms; Glioma; Head and Neck Neoplasms; Low-grade Glioma; Lung Neoplasms; Meningioma
상세
MNPR-101-Lu177MNPR-101-PCTA-177Lu; MNPR-101-Lu177Phase 1 ClinicalMonopar Therapeutics IncCarcinoma, Transitional Cell; Colorectal Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms
상세
MNPR-101-ZrMNPR-101-Zr; MNPR-101-DFO*-89ZrPhase 1 ClinicalMonopar Therapeutics Inc, Northstar Medical Radioisotopes LlcCarcinoma, Transitional Cell; Colorectal Neoplasms; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms
상세
KMHH-03KMHH-03; KMHH03Phase 1 ClinicalBeijing Kangming Haihui Biological Technology Co LtdBreast Neoplasms
상세
  • 분자 정보
  • 제품 목록
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호